What is the recommended management for flank folliculitis in a patient receiving testosterone replacement therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Flank Folliculitis in Testosterone Replacement Therapy

Treat the folliculitis with standard topical or oral antibiotics while continuing testosterone therapy at a reduced dose, and consider switching to a different testosterone formulation if the current one is causing local skin reactions.

Understanding the Connection

Folliculitis is a recognized dermatologic adverse effect of testosterone replacement therapy (TRT). Acne and folliculitis occur in 0.6%-9.1% of patients on TRT, with injectable formulations associated with higher rates than topical or oral preparations 1. The Endocrine Society guidelines specifically identify formulation-specific adverse effects, including skin reactions at application sites for patches and local reactions (pain, soreness, erythema, swelling, nodules, or furuncles) for intramuscular injections 2, 3.

Management Algorithm

Step 1: Assess Severity and Location

  • Document the extent and distribution of folliculitis on the flanks
  • Determine if this is related to application site (for transdermal products) or systemic androgen effect
  • Rule out other causes: bacterial folliculitis, fungal infection, or mechanical irritation

Step 2: Treat the Folliculitis Directly

  • For mild cases: Topical antibiotics (clindamycin) or benzoyl peroxide
  • For moderate-to-severe cases: Oral antibiotics (doxycycline or minocycline)
  • For refractory cases: Consider oral isotretinoin, which has shown 90% stable remission rates in severe follicular conditions 4

Step 3: Modify Testosterone Therapy

Do not discontinue testosterone if clinically indicated, but optimize the regimen:

  • If using transdermal patches: Switch to gel or injectable formulation, as patches cause skin reactions in up to 66% of users versus 5% with gels 3
  • If using injectable testosterone: Consider reducing dose or switching to more frequent, smaller injections (50-100 mg weekly instead of 200-300 mg every 2-3 weeks) to minimize peak testosterone levels that may exacerbate folliculitis 2
  • If using gel: Ensure proper application technique and consider oral testosterone undecanoate (if available) which has the lowest acne incidence 1

Step 4: Monitor Testosterone Levels

Measure serum testosterone 2-3 months after any formulation change:

  • Target mid-normal range (450-600 ng/dL)
  • For injectable testosterone enanthate/cypionate: measure midway between injections
  • For transdermal gel: measure anytime after 1 week of use
  • Adjust dose to maintain therapeutic levels while minimizing androgenic skin effects 2, 5

Critical Monitoring Points

The Endocrine Society guidelines mandate evaluation at 3 months after treatment initiation and annually thereafter to assess adverse effects 2. At each visit, specifically evaluate formulation-specific adverse effects, including examination of skin at application sites or injection sites 5.

Common Pitfalls to Avoid

  1. Do not stop testosterone abruptly in symptomatic hypogonadal men, as this will worsen their underlying condition without necessarily resolving the folliculitis immediately
  2. Do not assume all folliculitis is infectious - androgenic folliculitis may not respond to antibiotics alone and requires formulation adjustment 6
  3. Do not ignore patient preference - adherence improves when formulation matches lifestyle, so involve the patient in choosing an alternative delivery method
  4. Do not overlook exacerbating factors - long-term testosterone use may predispose to follicular occlusion disorders, particularly with repeated skin trauma 7

Special Considerations

If folliculitis persists despite formulation changes and standard treatments, consider:

  • Dermatology referral for trichoscopy and possible biopsy to rule out dissecting cellulitis or other follicular occlusion disorders 7
  • Temporary dose reduction (while maintaining therapeutic benefit) until skin clears
  • In severe refractory cases, oral isotretinoin under dermatologic supervision 4

The goal is to maintain the benefits of testosterone therapy (improved sexual function, body composition, bone density, and quality of life) 8 while managing the dermatologic side effect through formulation optimization and targeted skin treatment.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.